Clinical trials: Cancer of the Prostate
Small Cell Neuroendocrine Carcinoma, Prostate Cancer
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Despite the low androgen receptor (AR) transcriptional activity of treatment-emergent small cell neuroendocrine prostate cancer, there is persistent AR expression observed in the majority of treatment-emergent small-cell…
- Conditions
- Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
- Trial name
- NCT04926181
- Testing
- Apalutamide, Cetrelimab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rahul Aggarwal
Prostatic Neoplasms, Metastases, Neoplasm
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer
- Trial name
- NCT00055471
- Testing
- ZD4054 10 mg, ZD4054 15 mg, ZD4054 22.5 mg
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Prostate Cancer, Bladder Cancer
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.
- Conditions
- Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT00199849
- Testing
- NY-ESO-1 Plasmid DNA Cancer Vaccine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ludwig Institute for Cancer Research
Prostate Cancer
RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of…
- Trial name
- Restore (NCT02090114)
- Testing
- Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate
- Where
- 2 sites in United States
- Volunteers
- 112 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Genetic Polymorphism
Satraplatin and Prednisone to Treat Prostate Cancer
Background: Satraplatin is an experimental drug that may be of benefit to patients with prostate cancer. Prednisone is approved for treating prostate cancer.
- Trial name
- NCT00634647
- Testing
- Satraplatin, prednisone
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
This phase I/II trial studies the side effects of avelumab when given in different combinations with utomilumab, anti-OX40 antibody PF-04518600, and radiation therapy in treating patients with malignancies that have spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03217747
- Testing
- Avelumab, Ivuxolimab, Radiation Therapy
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy
The purpose of the proposed research is to test and validate a Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI) interpretation and identification of clinically significant tumor site(s).
- Trial name
- NCT03585660
- Testing
- Diagnostic MRI, Diagnostic Prostate Biopsy, Risk Map DSS tool
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- University of Chicago
Healthy
Adherence Dynamics for Whole Food Interventions in African-American Men
The purposes of this study are to explore the dynamics of adherence, using a simple whole food intervention strategy, both prior to and during the intervention period and to identify nutrient shifts in self-selected diets and to…
- Trial name
- DAPH (NCT01408459)
- Testing
- Tomato Product, Control
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Prostate Cancer
Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury
Lovastatin may protect against late effects of radiation therapy in patients with prostate cancer
- Trial name
- NCT00580970
- Testing
- lovastatin
- Where
- 3 sites in United States
- Volunteers
- 73 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Modeling Clinical Failure in Prostate Cancer Patients Based on a Two-stage Statistical Model
Biomarker series can indicate disease progression and predict clinical endpoints. When a treatment is prescribed depending on the biomarker, confounding by indication might be introduced if the treatment modifies the marker…
- Trial name
- PREDYC (NCT03979079)
- Testing
- external beam radiation therapy
- Where
- France
- Volunteers
- 2,384 people
- Sponsor
- Institut Bergonié
Prostatic Neoplasms, Castration-Resistant
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone…
- Trial name
- NCT05520138
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 5,506 people
- Sponsor
- Pfizer
Prostate Cancer, Prostate Adenocarcinoma
Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)
This study will investigate the safety, tolerability, and effectiveness of giving a higher dose to the part of the prostate which contains the cancer while giving a standard radiation dose to the entire prostate.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01856855
- Testing
- Stereotactic Body Radiation Therapy with Integrated Boost
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- John Fiveash, MD
Prostate Cancer
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan.
- Trial name
- NCT02559115
- Testing
- 68Ga-RM2 (RM2), PET/CT Scan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
This study will evaluate the response rate of MLN8237 in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer (NEPC).
- Conditions
- Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer, Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
- Trial name
- NCT01799278
- Testing
- MLN8237
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Eligible patients will be enrolled in one of 4 cohorts where each cohort will allow 3 patients to be on study. Patients will receive both study drugs on escalated dosing schedule until the maximum of 400 mg PO BID is reached for…
- Trial name
- NCT00424385
- Testing
- Gleevec + Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oncology Specialists, S.C.
Prostate Cancer
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
This is a single arm study of 11 men with treatment refractory metastatic Castrate Resistant Prostate Cancer (CRPC) who will receive temsirolimus IV at a dose of 25 mg weekly until progression.
- Trial name
- NCT00887640
- Testing
- Temsirolimus, Diphenhydramine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Prostate Cancer Metastatic to Bone
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve men with oligometastatic prostate cancer to the bone.
- Trial name
- RROPE (NCT03304418)
- Testing
- Radium Ra 223 Dichloride, Radiation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
This is an open label randomized phase II study for prostate cancer patients who have disease progression after hormonal therapy.
- Conditions
- Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
- Trial name
- NCT01313559
- Testing
- Pasireotide, Everolimus, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Castrate-resistant Prostate Cancer
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
This is a multi-national, multi-center, open-label, single-arm extension study for the prolongation of bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer.
- Trial name
- NCT01824342
- Testing
- Denosumab
- Where
- 9 sites in Czechia, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.